Use of Lidocaine in Rapid Sequence Induction

Condition(s) targeted: Hemodynamic Response

Intervention: Lidocaine (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Athens

Lidocaine has been shown to blunt the cardiovascular response to endotracheal intubation. The incidence of hypertension, tachycardia and dysrhythmias due to laryngoscopy may be increased in patients that receive rapid sequence induction and intubation, where opioids are spared and intravenous anesthetic agents are not titrated step by step. Our hypothesis was that lidocaine when administered intravenously in patients who undergo rapid sequence induction may not only blunt the hemodynamic response to intubation, but may also increase the anesthetic depth (as assessed by BIS), thus further reducing the possibility of hypertension, arrhythmias and also awareness.

Official title: Impact of Lidocaine on Anesthetic Depth During Rapid Sequence Induction

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)

Primary outcome: BIS changes after lidocaine administration in rapid sequence induction

Secondary outcome:

change in blood pressure

change in Heart rate

Minimum age: 20 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- reason for rapid sequence induction (emergency, reflux),

- ASA I-II,

- no antihypertensive drugs,

- no antiarrhythmic drugs

Exclusion Criteria :

Aretaieio Hospital, University of Athens, Athens, Attiki 11528, Greece

Starting date: October 2008
Last updated: August 23, 2011